Retatrutide

Every batch ships with a batch code printed on the vial. The matching independent lab report — identity, purity, and composition — independently lab-tested results — is linked on the product page and also available from your order page after purchase.

We recommend it — especially if you are pregnant, nursing, managing a medical condition, or combining peptides with prescribed medication. Our product pages are educational. They are not medical advice and they do not replace a conversation with a qualified practitioner.

Orders placed before 14:00 CET Monday–Friday ship the same business day from our European fulfilment centre in The Hague, Netherlands. Standard tracked EU delivery arrives in 2–4 business days; express options are available at checkout.

Research-only means the compound has not been approved by the EMA or any national medicines authority for medical use, and is sold solely for in-vitro and laboratory research. It is not a supplement, a cosmetic, or a medicine, and it carries no claims for human consumption.

No. Retatrutide is a triple agonist of GLP-1, GIP, and glucagon receptors developed by Eli Lilly and currently in Phase 3 trials (TRIUMPH programme). It is not approved by the EMA or FDA, so it cannot be prescribed. Phase 2 data showed up to ~24 percent body-weight reduction at 48 weeks.

Across SUSTAIN, SURPASS, SURMOUNT, and TRIUMPH trials, the dominant adverse events for semaglutide, tirzepatide, and retatrutide are gastrointestinal: nausea, vomiting, diarrhoea, constipation, and abdominal discomfort, usually mild-to-moderate and concentrated during dose titration.

A prescription peptide (e.g. Wegovy, Mounjaro, Vyleesi, Zadaxin in the relevant jurisdictions) has been through EMA or national-authority review, carries an authorised indication, and is dispensed by a pharmacy against a script. A research peptide is a reference-grade compound sold for laboratory use only.

Bring both the lyophilised vial and the bacteriostatic water to room temperature, equalise pressure with a sterile vented needle, then inject the solvent slowly down the side of the vial. Swirl gently — never shake — until clear, and refrigerate at 2–8 °C.

The calculation is peptide mass (mg) ÷ desired concentration (mg/mL) = volume of bacteriostatic water in mL. For example, a 5 mg vial at 1 mg/mL needs 5 mL; at 2 mg/mL, 2.5 mL. Every Peptyds product page carries a suggested reconstitution volume tuned to the vial size.

Most lyophilised peptides reconstituted with bacteriostatic water remain stable for 28–30 days at 2–8 °C, protected from light. A handful of short, fragile sequences — Epithalon among them — drop to roughly 14 days. Never freeze a reconstituted vial.

Across published trials and case series, the most frequent reported events are injection-site reactions (redness, induration, transient discomfort), headache, mild nausea, and temporary fatigue. GLP-1 and dual-agonist class peptides add dose-dependent gastrointestinal effects.

Peptides are not appropriate for anyone who is pregnant, nursing, planning conception, under 18, managing active cancer, or on immunosuppressants — and competitive athletes governed by WADA must avoid every peptide on the prohibited list. Anyone with a personal or family history of melanoma should specifically avoid melanocortin-receptor agonists.